{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T23:14:21Z","timestamp":1774826061189,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejca.2021.12.015","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T05:45:54Z","timestamp":1642139154000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus"],"prefix":"10.1016","volume":"163","author":[{"given":"Victoria","family":"Atkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-153X","authenticated-orcid":false,"given":"Jean J.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lev","family":"Demidov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Ryll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiya","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2021.12.015_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2021.12.015_bib2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.12.015_bib3","doi-asserted-by":"crossref","first-page":"S1175","DOI":"10.1016\/j.annonc.2020.08.2276","article-title":"Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial","volume":"31","author":"Eggermont","year":"2020","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2021.12.015_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.12.015_bib5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.12.015_bib6","series-title":"Presented at: 2017 ESMO Congress 8-12","article-title":"COMBI-AD: adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E\/K\u2013mutant melanoma","author":"Hauschild","year":"2017"},{"issue":"20","key":"10.1016\/j.ejca.2021.12.015_bib7","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.12.015_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdu529","article-title":"Characteristics of pyrexia in BRAFV600E\/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I\/II clinical trial","volume":"26","author":"Menzies","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"10.1016\/j.ejca.2021.12.015_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ajco.12656","article-title":"Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists","volume":"12","author":"Atkinson","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.015_bib10","article-title":"Data on file (BRF115532\/DRB436F2301 clinical study report; 2017)","author":"Novartis Pharmaceuticals Corporation","year":"2017","journal-title":"Novartis Pharmaceuticals Corporation"},{"issue":"9","key":"10.1016\/j.ejca.2021.12.015_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.12.015_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.015_bib13","series-title":"Oral presentation at: 14th International Congress of the Society for Melanoma Research; 18-21 October 2017. Brisbane, Australia","article-title":"Efficacy outcomes in the phase 3 COMBI-AD study of adjuvant dabrafenib plus trametinib vs placebo in patients with stage III BRAF V600E\/K-mutant melanoma","author":"Long","year":"2017"},{"key":"10.1016\/j.ejca.2021.12.015_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.05.005","article-title":"Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","volume":"153","author":"Schadendorf","year":"2021","journal-title":"Eur J Cancer"},{"issue":"15 suppl","key":"10.1016\/j.ejca.2021.12.015_bib15","article-title":"Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients with BRAF V600\u2013mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib in the COMBI-i trial","volume":"39","author":"Ascierto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.015_bib16","series-title":"Tafinlar (dabrafenib) [summary of product characteristics]","year":"2021"},{"key":"10.1016\/j.ejca.2021.12.015_bib17","series-title":"Mekinist (trametinib) [summary of product characteristics]","year":"2021"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.015_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2021.12.015_bib19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.015_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CMR.0000000000000654","article-title":"Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)","volume":"30","author":"Atkinson","year":"2020","journal-title":"Melanoma Res"},{"issue":"suppl 15","key":"10.1016\/j.ejca.2021.12.015_bib21","article-title":"Management of pyrexia in metastatic melanoma patients: a real-world clinical experience survey study","volume":"38","author":"Satija","year":"2020","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ejca.2021.12.015_bib22","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2021.12.015_bib23","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.12.015_bib24","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:00Z","timestamp":1760733300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":24,"alternative-id":["S0959804921012867"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}